Hoenle (HNL.DE) Stock Price
Hoenle Price
Over the last 19 years Hoenle grew revenue by 7.5% annually, reaching 93.68 M EUR. Earnings per share have grown at 4.6% per year over the last 13 years. For Hoenle, the net margin of -3.4% is broadly stable versus -4.2% a few years ago. At today's price the dividend yield works out to roughly 2.67%. The consensus 12-month price target for Hoenle is 19.38 EUR, about 159.1% above where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.
Hoenle stock price
Hoenle business model & stock analysis
Frequently asked questions about Hoenle
The business model of Dr Hoenle AG revolves around providing innovative UV technology solutions. As a leading manufacturer of UV systems, the company offers a wide range of products and services. Dr Hoenle AG specializes in developing and producing UV lamps, LED modules, and systems for various industries like automotive, printing, and electronics. With a focus on sustainability and energy efficiency, they deliver high-quality and reliable solutions for curing, bonding, and disinfection applications. Dr Hoenle AG also offers customer-specific solutions along with comprehensive technical support, ensuring their clients' needs are met effectively.
Dr Hoenle AG is primarily active in the fields of adhesives, coatings, and surface technology.
Dr Hoenle AG faces competition from various companies in the market. Some of its main competitors include UV technology providers such as IST METZ GmbH, Heraeus Noblelight GmbH, and Phoseon Technology. These competitors also specialize in manufacturing UV curing systems, UV lamps, and UV LED products. Furthermore, Dr Hoenle AG also contends with other companies involved in industrial adhesives, coatings, and printing industries. Being a leader in UV technology and offering innovative solutions, Dr Hoenle AG strives to maintain its competitive advantage and cater to the diverse needs of its customers.
Dr Hoenle AG is a German technology company specializing in UV technology and industrial adhesives. Founded in 1972 by Dr. Hans Hoenle, the company has an extensive history in providing innovative solutions for various industries. Dr Hoenle AG has established itself as a leader in the field of UV curing technology, offering products such as UV lamps, LED curing systems, and UV adhesives. With a commitment to research and development, the company has continuously improved its products, expanding its global presence and serving customers worldwide. Dr Hoenle AG's dedication to technological advancement and customer satisfaction has made it a trusted brand in the industry.
Dr Hoenle AG, a leading company in its industry, has achieved several significant milestones. The company's commitment to innovation and quality has allowed it to establish a strong presence in the market. Dr Hoenle AG has successfully expanded its product portfolio, offering advanced solutions tailored to various sectors. Furthermore, the company has secured numerous patents, demonstrating its dedication to research and development. Dr Hoenle AG's consistent growth and profitability have been instrumental in establishing its reputation as a reliable and successful player in the industry. As a result of these achievements, the company continues to attract investors and maintain its position as a market leader.
Dr Hoenle AG is primarily present in Germany, where its headquarters are located. Additionally, the company operates globally and has a significant presence in various countries and regions worldwide. With its advanced technologies and high-quality products, Dr Hoenle AG serves customers across Europe, especially in countries like Austria, Switzerland, and France. The company also has a significant presence in North America, catering to customers in the United States and Canada. Overall, Dr Hoenle AG has established itself as a prominent player in the global market, offering innovative solutions and meeting the needs of customers in multiple countries and regions.
Dr Hoenle AG represents values and a corporate philosophy centered on innovation, quality, and sustainability. As a leading company in the field of industrial UV technology, Dr Hoenle AG consistently strives to deliver cutting-edge solutions that meet the highest standards. The company is committed to creating sustainable products and processes, ensuring responsible resource management and minimizing its ecological footprint. With a focus on customer satisfaction, Dr Hoenle AG aims to provide reliable and efficient solutions that contribute to the success and growth of its clients. By continuously investing in research and development, Dr Hoenle AG remains at the forefront of technological advancements, delivering value to its stakeholders and maintaining a strong market presence.
Analysts currently set an average price target of 18.36 EUR for the Hoenle stock (median: 19.38 EUR), implying +145.5 % versus the latest price. The consensus is based on 6 analyst ratings.
7 analysts currently rate the Hoenle stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Hoenle to generate revenue of 93.60 M EUR and earnings per share of -0.20 EUR.
The Hoenle share (HNL.DE) is listed on 8 stock exchanges, including: London (0O27.L), SIX (Zürich) (HNL.SW), XETRA (HNL.DE), Frankfurt (HNL.F), München (HNL.MU), Düsseldorf (HNL.DU), Hamburg (HNL.HM).
Dr Hoenle AG is an internationally leading provider of UV technology for industrial applications. The company was founded in 1972 and is headquartered in Gräfelfing near Munich. With around 600 employees and a turnover of almost 100 million euros, the company is a significant player in its field. The business model of Dr Hoenle AG is based on the development, production, and sale of UV technology for a variety of applications. The company offers a wide range of products, divided into three divisions: UV technology for surface disinfection, industrial applications, and 3D printing. The first division includes products for surface disinfection, which are mainly used in medical facilities and the food industry. For example, this includes UV-C devices for air disinfection and surface sterilization. These devices are in high demand during the COVID-19 pandemic, as they effectively act against viruses and bacteria. The second division is the industrial application of UV technology. Here, Dr Hoenle offers a variety of products that can be used in different industries. This includes UV dryers for the printing industry, UV adhesives for automotive construction, and UV coatings for surfaces. The third division is 3D printing, for which Dr Hoenle has developed special UV-LED systems. These enable fast and precise curing of resins used in additive manufacturing. The applications range from prototype production to the production of series components. The business model of Dr Hoenle AG is based on a strong research and development department as well as close cooperation with customers from various industries. The company focuses on continuous innovation and aims to improve the efficiency and sustainability of industrial processes. In order to successfully implement the business model, the company relies on an international orientation. Dr Hoenle is represented in over 60 countries worldwide and operates its own sales and service companies in Europe, Asia, and the USA. In summary, Dr Hoenle AG is an innovative company specializing in UV technology for a variety of applications. The wide product range includes products for surface disinfection, industrial applications, and 3D printing. The business model is based on strong research and development, international orientation, and close cooperation with customers from various industries.
The expected revenue of Hoenle is 93.60 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hoenle is -1.21 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hoenle is currently -37.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hoenle stock.
The price-to-sales ratio (P/S) of Hoenle is currently 0.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hoenle stock.
The Eulerpool Quality Score for Hoenle is 0/10.
The ISIN of Hoenle is DE0005157101. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Hoenle is 515710. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Hoenle is HNL.DE. The ticker symbol is used to trade Hoenle shares on the stock exchange.
Hoenle stock
All fundamentals and in-depth analysis of Hoenle
Our stock analysis for Hoenle stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hoenle. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.